fda bpc-157 category 2 bulk drug substance compounding list The U.S. Food and Administration is moving toward allowing pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York FDA's own advisory committee voted
FDA's own advisory committee voted 8 6 Thursday. BPC 157, on the compounding list now, for ulcerative colitis. FDA staff argued against it, laid out the data gaps, the whole case. Panel overruled them FDA considers adding a dozen peptides to its bulk drug compounding list RAPS Updated 2026 FDA Category 2 peptide list As the science and regulations continue to develop, it's important to work with providers who stay informed and prioritize safe, medically guided protocols. At BPC 157 FDA Approval Status 2026: Clinical Trials FDA panel backs compounded BPC 157, KPV peptides in win for RFK Jr. STAT FDA Peptide Reclassification 2026: What It Means for Providers
Pay in 4 interest-free payments of $6.88 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 3 - Aug 8



